Dr. Iqbal on HER2-Driven Gastric Cancer

Syma Iqbal, MD
Published: Wednesday, Nov 14, 2018



Syma Iqbal, MD, an associate professor of clinical medicine at the Keck School of Medicine, University of Southern California, discusses the need to discover more reliable biomarkers in gastric cancer.

To date, the only consistent biomarker for gastric cancer has been HER2, Iqbal says. Patients with HER2-positive disease benefit from HER2 suppression in the frontline setting with targeted agents such as trastuzumab (Herceptin). Other than HER2, the only other biomarker that has shown potential in gastric cancer has been PD-L1, which is thought to be predictive of immunotherapy response.

PD-L1 expression has been particularly effective in other diseases like lung cancer and melanoma, but there are still unanswered questions regarding its use in gastric cancer. Therefore, Iqbal says she is unsure if she’s ready to consider PD-L1 as a biomarker in routine clinical practice.

Iqbal adds that even the HER2 story has had its caveats in this space. While targeted therapy works in the frontline setting, it has yet to show any benefit for second-line treatment.
SELECTED
LANGUAGE


Syma Iqbal, MD, an associate professor of clinical medicine at the Keck School of Medicine, University of Southern California, discusses the need to discover more reliable biomarkers in gastric cancer.

To date, the only consistent biomarker for gastric cancer has been HER2, Iqbal says. Patients with HER2-positive disease benefit from HER2 suppression in the frontline setting with targeted agents such as trastuzumab (Herceptin). Other than HER2, the only other biomarker that has shown potential in gastric cancer has been PD-L1, which is thought to be predictive of immunotherapy response.

PD-L1 expression has been particularly effective in other diseases like lung cancer and melanoma, but there are still unanswered questions regarding its use in gastric cancer. Therefore, Iqbal says she is unsure if she’s ready to consider PD-L1 as a biomarker in routine clinical practice.

Iqbal adds that even the HER2 story has had its caveats in this space. While targeted therapy works in the frontline setting, it has yet to show any benefit for second-line treatment.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Navigating New Sequencing Challenges for the Treatment of Hepatocellular CarcinomaAug 30, 20191.5
Publication Bottom Border
Border Publication
x